A new era of therapy for hepatitis C virus infection

Harita Nyalakonda, Netanya S. Utay

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose of review Previous treatments with pegylated interferon (PEG-IFN) and ribavirin for hepatitis C virus (HCV) infection resulted in significant adverse events and low cure rates, even with the addition of first-generation protease inhibitors. The standard of care for chronic HCV infection changed dramatically in 2013 with the approval of second-generation direct-acting antivirals, which led the way for IFN-free combination regimens. Recent findings All-oral combinations of direct-acting antivirals, with or without ribavirin, have shown high efficacy and are well tolerated in patients with the predominant genotypes, advanced fibrosis stages, and HIV co-infection. New fixed-dose co-formulations of direct-acting antivirals have allowed simpler regimens with shorter treatment durations and low rates of discontinuation, but are associated with substantial costs. Summary Since 2013, all-oral, IFN-free regimens with direct-acting antivirals have quickly become the mainstay of treatment for HCV infection as they provide high rates of sustained virologic response with a relatively short duration of treatment and low side-effect profile.

Original languageEnglish (US)
Pages (from-to)471-478
Number of pages8
JournalCurrent Opinion in Infectious Diseases
Volume28
Issue number5
DOIs
StatePublished - Jan 1 2015

Fingerprint

Virus Diseases
Hepacivirus
Antiviral Agents
Ribavirin
Chronic Hepatitis C
Therapeutics
Standard of Care
Protease Inhibitors
Coinfection
Interferons
HIV Infections
Fibrosis
Genotype
Costs and Cost Analysis

Keywords

  • antiviral therapy
  • direct-acting antivirals
  • hepatitis C virus
  • interferon-free

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Medicine(all)

Cite this

A new era of therapy for hepatitis C virus infection. / Nyalakonda, Harita; Utay, Netanya S.

In: Current Opinion in Infectious Diseases, Vol. 28, No. 5, 01.01.2015, p. 471-478.

Research output: Contribution to journalArticle

Nyalakonda, Harita ; Utay, Netanya S. / A new era of therapy for hepatitis C virus infection. In: Current Opinion in Infectious Diseases. 2015 ; Vol. 28, No. 5. pp. 471-478.
@article{b6753c9a2cbf42f980341a31e0b5639e,
title = "A new era of therapy for hepatitis C virus infection",
abstract = "Purpose of review Previous treatments with pegylated interferon (PEG-IFN) and ribavirin for hepatitis C virus (HCV) infection resulted in significant adverse events and low cure rates, even with the addition of first-generation protease inhibitors. The standard of care for chronic HCV infection changed dramatically in 2013 with the approval of second-generation direct-acting antivirals, which led the way for IFN-free combination regimens. Recent findings All-oral combinations of direct-acting antivirals, with or without ribavirin, have shown high efficacy and are well tolerated in patients with the predominant genotypes, advanced fibrosis stages, and HIV co-infection. New fixed-dose co-formulations of direct-acting antivirals have allowed simpler regimens with shorter treatment durations and low rates of discontinuation, but are associated with substantial costs. Summary Since 2013, all-oral, IFN-free regimens with direct-acting antivirals have quickly become the mainstay of treatment for HCV infection as they provide high rates of sustained virologic response with a relatively short duration of treatment and low side-effect profile.",
keywords = "antiviral therapy, direct-acting antivirals, hepatitis C virus, interferon-free",
author = "Harita Nyalakonda and Utay, {Netanya S.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/QCO.0000000000000190",
language = "English (US)",
volume = "28",
pages = "471--478",
journal = "Current Opinion in Infectious Diseases",
issn = "0951-7375",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A new era of therapy for hepatitis C virus infection

AU - Nyalakonda, Harita

AU - Utay, Netanya S.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose of review Previous treatments with pegylated interferon (PEG-IFN) and ribavirin for hepatitis C virus (HCV) infection resulted in significant adverse events and low cure rates, even with the addition of first-generation protease inhibitors. The standard of care for chronic HCV infection changed dramatically in 2013 with the approval of second-generation direct-acting antivirals, which led the way for IFN-free combination regimens. Recent findings All-oral combinations of direct-acting antivirals, with or without ribavirin, have shown high efficacy and are well tolerated in patients with the predominant genotypes, advanced fibrosis stages, and HIV co-infection. New fixed-dose co-formulations of direct-acting antivirals have allowed simpler regimens with shorter treatment durations and low rates of discontinuation, but are associated with substantial costs. Summary Since 2013, all-oral, IFN-free regimens with direct-acting antivirals have quickly become the mainstay of treatment for HCV infection as they provide high rates of sustained virologic response with a relatively short duration of treatment and low side-effect profile.

AB - Purpose of review Previous treatments with pegylated interferon (PEG-IFN) and ribavirin for hepatitis C virus (HCV) infection resulted in significant adverse events and low cure rates, even with the addition of first-generation protease inhibitors. The standard of care for chronic HCV infection changed dramatically in 2013 with the approval of second-generation direct-acting antivirals, which led the way for IFN-free combination regimens. Recent findings All-oral combinations of direct-acting antivirals, with or without ribavirin, have shown high efficacy and are well tolerated in patients with the predominant genotypes, advanced fibrosis stages, and HIV co-infection. New fixed-dose co-formulations of direct-acting antivirals have allowed simpler regimens with shorter treatment durations and low rates of discontinuation, but are associated with substantial costs. Summary Since 2013, all-oral, IFN-free regimens with direct-acting antivirals have quickly become the mainstay of treatment for HCV infection as they provide high rates of sustained virologic response with a relatively short duration of treatment and low side-effect profile.

KW - antiviral therapy

KW - direct-acting antivirals

KW - hepatitis C virus

KW - interferon-free

UR - http://www.scopus.com/inward/record.url?scp=84948682797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948682797&partnerID=8YFLogxK

U2 - 10.1097/QCO.0000000000000190

DO - 10.1097/QCO.0000000000000190

M3 - Article

VL - 28

SP - 471

EP - 478

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

SN - 0951-7375

IS - 5

ER -